New York Times Updates Article on Controversial AI Startup

The newspaper made substantial changes to its initial profile of Medvi after facing criticism for omitting key details about the company's legal and regulatory issues.

Apr. 10, 2026 at 6:18pm

Got story updates? Submit your updates here. ›

A highly detailed, luminous 3D illustration of a complex network of interconnected circuits and data streams, conceptually representing the AI algorithms used by the Medvi startup to market telehealth services and weight loss drugs.An intricate visualization of the AI technology powering Medvi's controversial healthcare marketing platform.NYC Today

The New York Times recently published a profile of the startup Medvi, which uses AI technology to market telehealth services and compounding pharmacies that sell weight loss drugs. However, the initial article failed to mention the legal and regulatory scrutiny Medvi was facing. After receiving backlash from readers, the Times updated the piece to provide a more balanced perspective on the company.

Why it matters

The incident highlights the challenges media outlets face in thoroughly vetting startups, especially those operating in emerging and potentially controversial industries like AI-powered healthcare marketing. It also underscores the importance of transparency and accountability in journalism, particularly when reporting on companies that may be engaging in questionable business practices.

The details

Medvi is a startup that uses AI algorithms to help telehealth providers and compounding pharmacies market and sell weight loss drugs, including GLP-1 medications. The initial New York Times profile praised the company's technology without mentioning that Medvi was facing legal actions and regulatory scrutiny over its business practices.

  • The New York Times published its initial profile of Medvi on April 5, 2026.
  • After receiving criticism from readers, the Times updated the article on April 10, 2026 to include information about the legal and regulatory issues facing Medvi.

The players

New York Times

A prominent American newspaper known for its in-depth reporting and high journalistic standards.

Medvi

A startup that uses AI technology to market telehealth services and compounding pharmacies that sell weight loss drugs, including GLP-1 medications.

Got photos? Submit your photos here. ›

What’s next

The New York Times has stated that it will review its editorial processes to ensure more thorough vetting of startups and companies in the future, particularly those operating in emerging or potentially controversial industries.

The takeaway

This incident underscores the importance of responsible journalism and the need for media outlets to provide balanced, well-researched coverage, even of high-profile startups. It also highlights the challenges of reporting on rapidly evolving industries like AI-powered healthcare marketing, where regulatory frameworks may still be developing.